These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
158 related articles for article (PubMed ID: 38526177)
1. Oncogenic Roles of Laminin Subunit Gamma-2 in Intrahepatic Cholangiocarcinoma via Promoting EGFR Translation. Zhang J; Ji F; Tan Y; Zhao L; Zhao Y; Liu J; Shao L; Shi J; Ye M; He X; Jin J; Zhao B; Huang J; Roessler S; Zheng X; Ji J Adv Sci (Weinh); 2024 Jun; 11(21):e2309010. PubMed ID: 38526177 [TBL] [Abstract][Full Text] [Related]
2. MUC13 promotes intrahepatic cholangiocarcinoma progression via EGFR/PI3K/AKT pathways. Tiemin P; Fanzheng M; Peng X; Jihua H; Ruipeng S; Yaliang L; Yan W; Junlin X; Qingfu L; Zhefeng H; Jian L; Zihao G; Guoxing L; Boshi S; Ming Z; Qinghui M; Desen L; Lianxin L J Hepatol; 2020 Apr; 72(4):761-773. PubMed ID: 31837357 [TBL] [Abstract][Full Text] [Related]
3. Silencing of LAMC2 Reverses Epithelial-Mesenchymal Transition and Inhibits Angiogenesis in Cholangiocarcinoma via Inactivation of the Epidermal Growth Factor Receptor Signaling Pathway. Pei YF; Liu J; Cheng J; Wu WD; Liu XQ Am J Pathol; 2019 Aug; 189(8):1637-1653. PubMed ID: 31345467 [TBL] [Abstract][Full Text] [Related]
4. Nucleolin lactylation contributes to intrahepatic cholangiocarcinoma pathogenesis via RNA splicing regulation of MADD. Yang L; Niu K; Wang J; Shen W; Jiang R; Liu L; Song W; Wang X; Zhang X; Zhang R; Wei D; Fan M; Jia L; Tao K J Hepatol; 2024 Oct; 81(4):651-666. PubMed ID: 38679071 [TBL] [Abstract][Full Text] [Related]
5. Membrane RRM2-positive cells represent a malignant population with cancer stem cell features in intrahepatic cholangiocarcinoma. Zhao Y; Xue S; Wei D; Zhang J; Zhang N; Mao L; Liu N; Zhao L; Yan J; Wang Y; Cai X; Zhu S; Roessler S; Ji J J Exp Clin Cancer Res; 2024 Sep; 43(1):255. PubMed ID: 39243109 [TBL] [Abstract][Full Text] [Related]
6. LAMC2 promotes EGFR cell membrane localization and acts as a novel biomarker for tyrosine kinase inhibitors (TKIs) sensitivity in lung cancer. Tong D; Wang X; Liu L; Wen T; Chen Q; Huang C Cancer Gene Ther; 2023 Nov; 30(11):1498-1512. PubMed ID: 37542131 [TBL] [Abstract][Full Text] [Related]
7. ST3GAL1 Promotes Malignant Phenotypes in Intrahepatic Cholangiocarcinoma. Chen F; Gao K; Li Y; Li Y; Wu Y; Dong L; Yang Z; Shi J; Guo K; Gao Q; Lu H; Zhang S Mol Cell Proteomics; 2024 Sep; 23(9):100821. PubMed ID: 39069074 [TBL] [Abstract][Full Text] [Related]
8. HSF1 is a prognostic determinant and therapeutic target in intrahepatic cholangiocarcinoma. Cigliano A; Gigante I; Serra M; Vidili G; Simile MM; Steinmann S; Urigo F; Cossu E; Pes GM; Dore MP; Ribback S; Milia EP; Pizzuto E; Mancarella S; Che L; Pascale RM; Giannelli G; Evert M; Chen X; Calvisi DF J Exp Clin Cancer Res; 2024 Sep; 43(1):253. PubMed ID: 39243039 [TBL] [Abstract][Full Text] [Related]
9. Unveiling the role of HP1α-HDAC1-STAT1 axis as a therapeutic target for HP1α-positive intrahepatic cholangiocarcinoma. Xiong F; Wang D; Xiong W; Wang X; Huang WH; Wu GH; Liu WZ; Wang Q; Chen JS; Kuai YY; Wang B; Chen YJ J Exp Clin Cancer Res; 2024 May; 43(1):152. PubMed ID: 38812060 [TBL] [Abstract][Full Text] [Related]
10. Aberrant fucosylation sustains the NOTCH and EGFR/NF-κB pathways and has a prognostic value in human intrahepatic cholangiocarcinoma. Ament CE; Steinmann S; Evert K; Pes GM; Ribback S; Gigante I; Pizzuto E; Banales JM; Rodrigues PM; Olaizola P; Wang H; Giannelli G; Chen X; Evert M; Calvisi DF Hepatology; 2023 Dec; 78(6):1742-1754. PubMed ID: 36789652 [TBL] [Abstract][Full Text] [Related]
11. Fragile X mental retardation protein in intrahepatic cholangiocarcinoma: regulating the cancer cell behavior plasticity at the leading edge. Carotti S; Zingariello M; Francesconi M; D'Andrea L; Latasa MU; Colyn L; Fernandez-Barrena MG; Flammia RS; Falchi M; Righi D; Pedini G; Pantano F; Bagni C; Perrone G; Rana RA; Avila MA; Morini S; Zalfa F Oncogene; 2021 Jun; 40(23):4033-4049. PubMed ID: 34017076 [TBL] [Abstract][Full Text] [Related]
12. miR-885-5p inhibits proliferation and metastasis by targeting IGF2BP1 and GALNT3 in human intrahepatic cholangiocarcinoma. Lixin S; Wei S; Haibin S; Qingfu L; Tiemin P Mol Carcinog; 2020 Dec; 59(12):1371-1381. PubMed ID: 33052627 [TBL] [Abstract][Full Text] [Related]
13. New molecular mechanisms in cholangiocarcinoma: signals triggering interleukin-6 production in tumor cells and KRAS co-opted epigenetic mediators driving metabolic reprogramming. Colyn L; Alvarez-Sola G; Latasa MU; Uriarte I; Herranz JM; Arechederra M; Vlachogiannis G; Rae C; Pineda-Lucena A; Casadei-Gardini A; Pedica F; Aldrighetti L; López-López A; López-Gonzálvez A; Barbas C; Ciordia S; Van Liempd SM; Falcón-Pérez JM; Urman J; Sangro B; Vicent S; Iraburu MJ; Prosper F; Nelson LJ; Banales JM; Martinez-Chantar ML; Marin JJG; Braconi C; Trautwein C; Corrales FJ; Cubero FJ; Berasain C; Fernandez-Barrena MG; Avila MA J Exp Clin Cancer Res; 2022 May; 41(1):183. PubMed ID: 35619118 [TBL] [Abstract][Full Text] [Related]
14. Loss of Numb promotes hepatic progenitor expansion and intrahepatic cholangiocarcinoma by enhancing Notch signaling. Shu Y; Xu Q; Xu Y; Tao Q; Shao M; Cao X; Chen Y; Wu Z; Chen M; Zhou Y; Zhou P; Shi Y; Bu H Cell Death Dis; 2021 Oct; 12(11):966. PubMed ID: 34667161 [TBL] [Abstract][Full Text] [Related]
15. Overexpression of laminin-5 gamma-2 promotes tumorigenesis of pancreatic ductal adenocarcinoma through EGFR/ERK1/2/AKT/mTOR cascade. Kirtonia A; Pandey AK; Ramachandran B; Mishra DP; Dawson DW; Sethi G; Ganesan TS; Koeffler HP; Garg M Cell Mol Life Sci; 2022 Jun; 79(7):362. PubMed ID: 35699794 [TBL] [Abstract][Full Text] [Related]
16. A Mouse Model of Cholangiocarcinoma Uncovers a Role for Tensin-4 in Tumor Progression. Di-Luoffo M; Pirenne S; Saandi T; Loriot A; Gérard C; Dauguet N; Manzano-Núñez F; Alves Souza Carvalhais N; Lamoline F; Cordi S; Konobrocka K; De Greef V; Komuta M; Halder G; Jacquemin P; Lemaigre FP Hepatology; 2021 Sep; 74(3):1445-1460. PubMed ID: 33768568 [TBL] [Abstract][Full Text] [Related]
18. ADAR1 promotes cisplatin resistance in intrahepatic cholangiocarcinoma by regulating BRCA2 expression through A-to-I editing manner. Liu Q; Huang CS; Chen S; Zhu YQ; Huang XT; Zhao GY; Xu QC; Shi YH; Li W; Wang R; Yin XY Cell Prolif; 2024 Oct; 57(10):e13659. PubMed ID: 38773866 [TBL] [Abstract][Full Text] [Related]
19. Comprehensive analysis of genomic mutation signature and tumor mutation burden for prognosis of intrahepatic cholangiocarcinoma. Zhang R; Li Q; Fu J; Jin Z; Su J; Zhang J; Chen C; Geng Z; Zhang D BMC Cancer; 2021 Feb; 21(1):112. PubMed ID: 33535978 [TBL] [Abstract][Full Text] [Related]
20. Overexpression of TBX3 suppresses tumorigenesis in experimental and human cholangiocarcinoma. Deng S; Lu X; Wang X; Liang B; Xu H; Yang D; Cui G; Yonemura A; Paine H; Zhou Y; Zhang Y; Simile MM; Urigo F; Evert M; Calvisi DF; Green BL; Chen X Cell Death Dis; 2024 Jun; 15(6):441. PubMed ID: 38909034 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]